Cathie Wood’s ARK ETFs have made a series of trades on Tuesday, April 9, 2024, as part of their regular portfolio adjustments. The trades included both purchases and sales across a variety of sectors, with a particular focus on technology and healthcare.

The largest transaction of the day was a sale of 51,316 shares of UiPath Inc (NYSE:), a company specializing in robotic process automation. This sale was spread across the ARKG and ARKX ETFs, with a total dollar value of $1,110,991. This move comes after a previous sale of UiPath shares last Wednesday, indicating a trend in ARK’s investment strategy.

Another significant sale was that of 9,973 shares of Incyte Corp (NASDAQ:), a biopharmaceutical company, through the ARKG ETF, amounting to $549,013. This sale may reflect ARK’s shifting focus within the biotech sector.

On the buying side, ARK invested heavily in Iridium Communications Inc (NASDAQ:), purchasing a total of 34,438 shares across the ARKQ and ARKX ETFs, with a total value of $875,413. This investment highlights ARK’s interest in satellite communication technologies.

Additionally, ARK bought 68,122 shares of Teladoc Inc (NYSE:NYSE:), a telemedicine company, across four different ETFs (ARKK, ARKW, ARKG, and ARKF), totaling $995,943. This purchase continues ARK’s bullish stance on the telehealth industry.

Other notable purchases included 12,647 shares of Roku Inc (NASDAQ:) and 52,700 shares of Recursion Pharmaceuticals (NASDAQ:RXRX), with total dollar values of $769,569 and $474,300, respectively. These trades are part of ARK’s ongoing investment in streaming technology and the pharmaceutical sector.

Smaller trades included the purchase of shares in companies like Archer Aviation Inc (NYSE:NYSE:), Crispr Therapeutics AG (NASDAQ:), Intellia Therapeutics Inc (NASDAQ:), Palantir Technologies Inc (NYSE:NYSE:), Personalis Inc (NASDAQ:), and 10X Genomics Inc (NASDAQ:TXG).

These daily trades offer investors insight into ARK’s latest investment moves and the strategic adjustments they are making within their ETF portfolios. Investors and market watchers will likely continue to monitor ARK’s activity for indications of broader market trends and shifts in investment focus.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.